PURPOSE: The purpose of this study was to determine the prognostic impact of epidermal growth factor receptor (EGFR) and Her2/neu protein expression in colorectal cancer. METHODS: Immunohistochemistry was performed in paraffin-embedded specimens of 106 colorectal carcinomas for the assessment of EGFR and Her-2 expression. The results were correlated with traditional clinicopathologic parameters and patient outcome. RESULTS: Membranous expression of EGFR was found in 50 cases (47.16%) and cytoplasmic expression in 32 cases (30.19%). Membranous overexpression of Her-2 was identified in six cases (5.66%) whereas cytoplasmic expression was found in 18 cases (16.98%). The correlation with other clinicopathologic parameters demonstrated a statistically significant expression of membranous EGFR in the older age group and a statistically significant expression of membranous Her-2 in patients with negative lymph nodes. None of the other parameters or patient prognosis was associated with EGFR or Her-2 membranous expression. Cytoplasmic expression was not related with any of aforementioned parameters. CONCLUSION: Conventional immunohistochemistry was unable to reveal any association between EGFR expression and outcome predicted by the biologic role of EGFR in tumor behavior. Her-2/neu is not a pivotal pathway in colorectal cancer progression because it seems to be expressed in early stages of colorectal cancer.
PURPOSE: The purpose of this study was to determine the prognostic impact of epidermal growth factor receptor (EGFR) and Her2/neu protein expression in colorectal cancer. METHODS: Immunohistochemistry was performed in paraffin-embedded specimens of 106 colorectal carcinomas for the assessment of EGFR and Her-2 expression. The results were correlated with traditional clinicopathologic parameters and patient outcome. RESULTS: Membranous expression of EGFR was found in 50 cases (47.16%) and cytoplasmic expression in 32 cases (30.19%). Membranous overexpression of Her-2 was identified in six cases (5.66%) whereas cytoplasmic expression was found in 18 cases (16.98%). The correlation with other clinicopathologic parameters demonstrated a statistically significant expression of membranous EGFR in the older age group and a statistically significant expression of membranous Her-2 in patients with negative lymph nodes. None of the other parameters or patient prognosis was associated with EGFR or Her-2 membranous expression. Cytoplasmic expression was not related with any of aforementioned parameters. CONCLUSION: Conventional immunohistochemistry was unable to reveal any association between EGFR expression and outcome predicted by the biologic role of EGFR in tumor behavior. Her-2/neu is not a pivotal pathway in colorectal cancer progression because it seems to be expressed in early stages of colorectal cancer.
Authors: Phillip R Stahl; Jessica Schnellert; Christina Koop; Ronald Simon; Andreas Marx; Jakob R Izbicki; Guido Sauter; Alexander Quaas Journal: Pathol Oncol Res Date: 2015-05-31 Impact factor: 3.201
Authors: Petros C Papagiorgis; Adamantia E Zizi; Sophia Tseleni; Ioannis N Oikonomakis; Nikolaos I Nikiteas Journal: Oncol Lett Date: 2012-02-28 Impact factor: 2.967
Authors: Nise H Yamaguchi; Ingrid A Mayer; Artur Malzyner; Carlos Jc de Andrade; Andre M Murad; Auro Del Giglio; Venancio Alves Journal: J Gastrointest Oncol Date: 2014-02
Authors: Cristina Teixidó; Rosó Marés; Miguel Aracil; Santiago Ramón y Cajal; Javier Hernández-Losa Journal: PLoS One Date: 2013-01-08 Impact factor: 3.240
Authors: Il Yong Shin; Na Young Sung; Youn Soo Lee; Taek Soo Kwon; Yoon Si; Yoon Suk Lee; Seong Taek Oh; In Kyu Lee Journal: Gut Liver Date: 2013-08-14 Impact factor: 4.519